← Eichor
Condition: Myotonic Dystrophy Type 1 Dm1 Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Myotonic Dystrophy Type 1 Dm1

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
EARLY_Phase 1 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06828588Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
Phase N/A · 1 location(s) · Seoul National University Hospital · NCT06928818Herombopag Treated T-DM1 Induced Platelet Reduction
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07257809Personalized Training for People With Rare Neuromuscular Disorders
NA · 5 location(s) · Oslo University Hospital · NCT06708468Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Phase N/A · 1 location(s) · Virginia Commonwealth University · NCT07700225Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological R
Phase N/A · 1 location(s) · Regina Elena Cancer Institute · NCT06272799Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Phase 2 · 13 location(s) · Dana-Farber Cancer Institute · NCT04620187Remote Assessments and Genetic Determinants of Myotonic Dystrophy
Phase N/A · 1 location(s) · University of Rochester · NCT07505342The United Kingdom National Registry for Myotonic Dystrophy
Phase N/A · 1 location(s) · Newcastle University · NCT04003363Pelvic Floor Muscle Training for Women with Myotonic Dystrophy
NA · 1 location(s) · Université de Sherbrooke · NCT06316778Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dys
Phase 1/Phase 2 · 20 location(s) · Dyne Therapeutics · NCT05481879The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
Phase 3 · 7 location(s) · Lupin Ltd. · NCT06523400Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
Phase N/A · 1 location(s) · Virginia Commonwealth University · NCT06747884An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
Phase 2 · 3 location(s) · PepGen Inc · NCT07220603Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
Phase 3 · 21 location(s) · Dyne Therapeutics · NCT07486934Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Phase N/A · 17 location(s) · Virginia Commonwealth University · NCT03981575A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer
Phase 3 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06830889A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
Phase 2 · 8 location(s) · PepGen Inc · NCT06667453Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy
Phase 1/Phase 2 · 11 location(s) · Arrowhead Pharmaceuticals · NCT06138743Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy
Phase N/A · 1 location(s) · University of Rochester · NCT07630389Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
Phase N/A · 1 location(s) · Shu Wang · NCT06693037Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Phase N/A · 1 location(s) · University of Rochester · NCT00082108JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT06846437Study of ATX-01 in Participants With DM1
Phase 1/Phase 2 · 12 location(s) · ARTHEx Biotech S.L. · NCT06300307A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
Phase 3 · 70 location(s) · GeneQuantum Healthcare (Suzhou) Co., Ltd. · NCT07673029Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Phase 2/Phase 3 · 14 location(s) · AMO Pharma Limited · NCT05004129DMCRN-02-001: Assessing Pediatric Endpoints in DM1
Phase N/A · 5 location(s) · Virginia Commonwealth University · NCT05224778A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Ge
Phase 1/Phase 2 · 9 location(s) · Sanofi · NCT06844214Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
Phase N/A · 1 location(s) · Massachusetts General Hospital · NCT06075693Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05532813
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.